<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Increased repolarization lability is known to be associated with the risk of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT)/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0006682'>Premature ventricular contractions</z:hpo> (<z:mp ids='MP_0010018'>PVCs</z:mp>) are excluded from the analysis of QT variability </plain></SENT>
<SENT sid="2" pm="."><plain>However, QT dynamics after <z:mp ids='MP_0010018'>PVCs</z:mp> is poorly understood </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We analyzed data of 33 patients with structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> (mean age 60.5 ± 12.1; 24 (73%) men; 26 (79%) whites; 22 (67%) ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>) and single-chamber <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implanted for primary (28 patients, 85%) or secondary prevention of SCD </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011675'>Arrhythmia</z:hpo> group comprised 16 patients with VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>/<z:hpo ids='HP_0011420'>death</z:hpo> outcomes </plain></SENT>
<SENT sid="5" pm="."><plain>Alive patients (n = 17) without VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> served as controls </plain></SENT>
<SENT sid="6" pm="."><plain>The baseline far-field (FF) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> electrogram (EGM) was recorded at rest </plain></SENT>
<SENT sid="7" pm="."><plain>RR and QT intervals of 15 sinus beats before and after <z:mp ids='MP_0010018'>PVC</z:mp> in 33 patients were analyzed </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:e sem="disease" ids="C0728731" disease_type="Disease or Syndrome" abbrv="">prematurity</z:e> index, C(i)Mean(RR), where C(i) is coupling interval, was used to select the most premature <z:mp ids='MP_0010018'>PVC</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>QT variability index (QTVI) was calculated </plain></SENT>
<SENT sid="10" pm="."><plain>Difference in QTVI was calculated as QTVI(diff) = QTVI(after)-QTVI(before.) RESULTS: In paired analysis QTVI significantly increased after <z:mp ids='MP_0010018'>PVC</z:mp> in controls (0.64 ± 1.02 vs. 0.26 ± 1.15; P = 0.046), but decreased in patients in the <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> group (0.16 ± 0.85 vs. 0.43 ± 0.84; P = 0.190) </plain></SENT>
<SENT sid="11" pm="."><plain>QTVI(diff) was significantly lower in patients with VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, as compared to controls (-0.197 ± 0.650 vs. 0.207 ± 0.723; P=0.030) </plain></SENT>
<SENT sid="12" pm="."><plain>In multivariate logistic regression after adjustment for the type of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and NYHA class the decrease in QTVI after <z:mp ids='MP_0010018'>PVC</z:mp> was associated with increased risk of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (OR 9.24; 95% CI 1.11-76.82; P=0.040) </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: Elevated at baseline QTVI is decreased during first 15 beats after <z:mp ids='MP_0010018'>PVC</z:mp> in patients at risk for VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> </plain></SENT>
</text></document>